title: Targeting the hypoxia pathway to treat pancreatic cancer.
abstract: The correlation between hypoxia and pancreatic cancer has long been discussed. Hao's research team made many efforts on revealing the oncogenic function of hypoxic inducible factor-1 (HIF-1) in pancreatic cancer progression and development in recent years. Based on their research, they linked micro-environmental regulation of pancreatic cancer and its clinical significance. Hao's research team suggests it is a promising approach to target HIF-1 for the management of pancreatic cancer progression and invasion.
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Lori A
authors.initials: LA
authors.lastname: Erickson
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: W Edward
authors.initials: WE
authors.lastname: Highsmith
authors.affiliation: University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA.
authors.forename: Peiwen
authors.initials: P
authors.lastname: Fei
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy* / Q000378:metabolism*; D051793:Hypoxia-Inducible Factor 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D051793:Hypoxia-Inducible Factor 1
keywords: HIF-1; hypoxia; pancreatic cancer